Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
ipo
3
×
life sciences
national blog main
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
vc
3
×
biogen
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
gene therapy
indiana blog main
indiana top stories
national
novartis
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
startups
texas blog main
texas top stories
venture capital
wisconsin blog main
wisconsin top stories
2025
accent therapeutics
acetylon pharmaceuticals
ad-comm
aducanumab
What
new
3
×
bio
ipo
medicines
roundup
activity
aiming
allogene
ambys
approvals
big
biogen
biotech
cancer
clamped
control
covid
crispr
deadly
deal
debuted
delays
developing
diseases
diversity
economic
fast
fda
formed
future
hot
immunotherapy
including
investors
isn’t
juno
launch
liver
lot
make
Language
unset
Current search:
ipo
×
vc
×
new
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?